Gene therapy: A promising candidate for cystic fibrosis treatment

An improved gene therapy treatment can cure mice with cystic fibrosis (CF). Cell cultures from CF patients, too, respond well to the treatment. Those are the encouraging results of a study presented by the Laboratory for Molecular Continue reading Gene therapy: A promising candidate for cystic fibrosis treatment

Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Vertex Pharmaceuticals (NASDAQ:VRTX) released outstanding third-quarter earnings on Wednesday with sales of both cystic fibrosis drugs, Orkambi and Kalydeco, selling like hotcakes. Continue reading Vertex Pharmaceuticals Incorporated: Profit on the Horizon

Vertex Turns Up the Heat on Cystic Fibrosis Challengers

Back in 2012, Vertex Pharmaceuticals (NASDAQ:VRTX) changed thousands of lives when it won approval to market Kalydeco to treat cystic fibrosis patients in the U.S. and EU. Cystic fibrosis, or CF, can be caused by one of many mutations Continue reading Vertex Turns Up the Heat on Cystic Fibrosis Challengers

Cystic Fibrosis Foundation Therapeutics Announces $7.5 Million Award to Discover New Therapies for Nonsense Mutations

Southern Research will use a sophisticated screening process to identify compounds in its chemical library that could promote the production of functional CFTR protein. In individuals with CF, a defective CFTR protein leads to Continue reading Cystic Fibrosis Foundation Therapeutics Announces $7.5 Million Award to Discover New Therapies for Nonsense Mutations

Discovery of Iron Metabolism-associated Gene Could Lead to New P. aeruginosa Treatments for Cystic Fibrosis Inhibition of PA4834 could contribute to the efficient eradication of P. aeruginosa in Cystic Fibrosis patients

http://cysticfibrosisnewstoday.com/2015/10/19/discovery-iron-metabolism-associated-gene-lead-new-p-aeruginosa-treatments-cystic-fibrosis/

Originally published in Cystic Fibrosis News Today
By Ana Pamplona, PhD

A new study entitled “A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus” published in the Scientific Reports journal by researchers from the PLUS Project for Medical Science and Yonsei Continue reading Discovery of Iron Metabolism-associated Gene Could Lead to New P. aeruginosa Treatments for Cystic Fibrosis Inhibition of PA4834 could contribute to the efficient eradication of P. aeruginosa in Cystic Fibrosis patients

Galapagos advances triple combination therapy in cystic fibrosis

GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro

– Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to Continue reading Galapagos advances triple combination therapy in cystic fibrosis

Doctors challenge Vertex over high price of cystic fibrosis drug

Originally published in the Boston Globe: https://www.bostonglobe.com/business/2015/07/20/researcher-and-group-doctors-challenge-vertex-price-new-cystic-fibrosis-drug/d5PZMlj6T6uzq0usm2xLEL/story.html#

By Globe Staff 

California scientist Paul M. Quinton learned that he has cystic fibrosis at age 19 and has spent his long career in his lab working on ways to cure it. Continue reading Doctors challenge Vertex over high price of cystic fibrosis drug

Two New Potent DF508-CFTR Correctors Offer Potential to Treat Cystic Fibrosis

An international group of researchers led by Aleksander Edelman from Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes) discovered two novel compounds that can target the genetic mutation that leads to a severe form of Cystic Fibrosis. Continue reading Two New Potent DF508-CFTR Correctors Offer Potential to Treat Cystic Fibrosis

DiscoveryBioMed Developing A New Small Molecule Monotherapy For Cystic Fibrosis Patients

DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. Continue reading DiscoveryBioMed Developing A New Small Molecule Monotherapy For Cystic Fibrosis Patients